Abklärung und Therapie von Refluxbeschwerden
Standard
Abklärung und Therapie von Refluxbeschwerden. / Morgner-Miehlke, A; Koop, H; Blum, A L; Hermans, M-L; Miehlke, S; Labenz, J.
In: Z GASTROENTEROL, Vol. 44, No. 5, 05.2006, p. 399-410.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Abklärung und Therapie von Refluxbeschwerden
AU - Morgner-Miehlke, A
AU - Koop, H
AU - Blum, A L
AU - Hermans, M-L
AU - Miehlke, S
AU - Labenz, J
PY - 2006/5
Y1 - 2006/5
N2 - The current guidelines of the German Society for Digestive Diseases (DGVS) endoscopy recommends for patients representing with reflux symptoms. In daily routine as well as in Guidelines from other countries and international guidelines, however, a symptom-based strategy for the management of patients with reflux disease is favoured. Since either strategies is dependent on specific clinical findings, neither can be recommended. The preference for one or the other strategy depends on the prevalence of so-called alarm symptoms, risk factors for a reflux carcinoma or Barrett's metaplasia, demographic factors, e. g., age and gender, patient's wish and initial response to empirical therapy with proton pump inhibitors (PPI). However, most patients with characteristic reflux symptoms without any alarm symptoms and/or other risk factors can be safely managed with a symptom-based strategy in acute and long-term care.
AB - The current guidelines of the German Society for Digestive Diseases (DGVS) endoscopy recommends for patients representing with reflux symptoms. In daily routine as well as in Guidelines from other countries and international guidelines, however, a symptom-based strategy for the management of patients with reflux disease is favoured. Since either strategies is dependent on specific clinical findings, neither can be recommended. The preference for one or the other strategy depends on the prevalence of so-called alarm symptoms, risk factors for a reflux carcinoma or Barrett's metaplasia, demographic factors, e. g., age and gender, patient's wish and initial response to empirical therapy with proton pump inhibitors (PPI). However, most patients with characteristic reflux symptoms without any alarm symptoms and/or other risk factors can be safely managed with a symptom-based strategy in acute and long-term care.
KW - Adenocarcinoma
KW - Anti-Ulcer Agents
KW - Barrett Esophagus
KW - Diagnosis, Differential
KW - Disease Progression
KW - Endoscopy, Digestive System
KW - Esophageal Neoplasms
KW - Esophagitis, Peptic
KW - Gastroesophageal Reflux
KW - Humans
KW - Long-Term Care
KW - Practice Guidelines as Topic
KW - Proton Pump Inhibitors
KW - Risk Factors
KW - Treatment Outcome
KW - English Abstract
KW - Journal Article
U2 - 10.1055/s-2006-926619
DO - 10.1055/s-2006-926619
M3 - SCORING: Zeitschriftenaufsatz
C2 - 16688658
VL - 44
SP - 399
EP - 410
JO - Z GASTROENTEROL
JF - Z GASTROENTEROL
SN - 0044-2771
IS - 5
ER -